StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$12.92−0.48 (-3.58%)

Close on Nov 16, 2026Market cap $172.91MP/E –Yield –

Anika Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Anika Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $500.00K. For fiscal 2025 it was -$5.68M, down 418.5% from the year before. The highest annual figure on record is $66.15M in fiscal 2014.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.68M-418.5%
FY2024Dec 31, 2024$1.78M-75.5%
FY2023Dec 31, 2023$7.28M-29.8%
FY2022Dec 31, 2022$10.37M+14.1%
FY2021Dec 31, 2021$9.10M–
FY2020Dec 31, 2020-$22.24M-156.7%
FY2019Dec 31, 2019$39.21M+41.7%
FY2018Dec 31, 2018$27.66M-44.7%
FY2017Dec 31, 2017$50.02M-8.0%
FY2016Dec 31, 2016$54.34M+4.7%
FY2015Dec 31, 2015$51.91M-21.5%
FY2014Dec 31, 2014$66.15M+77.0%
FY2013Dec 31, 2013$37.38M+54.2%
FY2012Dec 31, 2012$24.24M+34.9%
FY2011Dec 31, 2011$17.97M+65.5%
FY2010Dec 31, 2010$10.86M+57.8%
FY2009Dec 31, 2009$6.88M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.46M–
Q1 FY2026Mar 31, 2026-$4.08M–
Q4 FY2025Dec 31, 2025$1.96M+129.7%
Q3 FY2025Sep 30, 2025-$1.84M-203.5%
Q2 FY2025Jun 30, 2025-$2.90M–
Q1 FY2025Mar 31, 2025-$2.90M–
Q4 FY2024Dec 31, 2024$855.00K-96.8%
Q3 FY2024Sep 30, 2024$1.78M–
Q2 FY2024Jun 30, 2024-$80.00K–
Q1 FY2024Mar 31, 2024-$771.00K–
Q4 FY2023Dec 31, 2023$26.33M+45.3%
Q3 FY2023Sep 30, 2023-$6.08M–
Q2 FY2023Jun 30, 2023-$2.03M–
Q1 FY2023Mar 31, 2023-$10.95M–
Q4 FY2022Dec 31, 2022$18.12M–
Q3 FY2022Sep 30, 2022-$4.25M-245.7%
Q2 FY2022Jun 30, 2022-$1.62M-115.1%
Q1 FY2022Mar 31, 2022-$1.88M-167.2%
Q4 FY2021Dec 31, 2021-$7.35M–
Q3 FY2021Sep 30, 2021$2.92M–
Q2 FY2021Jun 30, 2021$10.72M–
Q1 FY2021Mar 31, 2021$2.80M-71.6%
Q4 FY2020Dec 31, 2020-$16.42M-409.7%
Q3 FY2020Sep 30, 2020-$9.84M-172.5%
Q2 FY2020Jun 30, 2020-$5.84M-143.6%
Q1 FY2020Mar 31, 2020$9.86M+41.6%
Q4 FY2019Dec 31, 2019$5.30M-52.8%
Q3 FY2019Sep 30, 2019$13.57M+34.5%
Q2 FY2019Jun 30, 2019$13.38M+5.4%
Q1 FY2019Mar 31, 2019$6.96M–
Q4 FY2018Dec 31, 2018$11.24M+4.1%
Q3 FY2018Sep 30, 2018$10.09M-12.1%
Q2 FY2018Jun 30, 2018$12.69M-32.2%
Q1 FY2018Mar 31, 2018-$6.36M-170.5%
Q4 FY2017Dec 31, 2017$10.79M-21.2%
Q3 FY2017Sep 30, 2017$11.47M-21.2%
Q2 FY2017Jun 30, 2017$18.73M–
Q1 FY2017Mar 31, 2017$9.02M–
Q4 FY2016Dec 31, 2016$13.70M–
Q3 FY2016Sep 30, 2016$14.57M–

More Anika Therapeutics figures

See a number that looks wrong?